This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
CURx Pharmaceuticals, Inc.
Drug Names(s): Corus 1040, tobramycin/phosphomycin for inhalation, fosfomycin:tobramycin for inhalation (FTI)
Description: GS 9310/11, formerly known as Corus 1040,is a proprietary formulation of combination tobramycin and phosphomycin for inhalation.
Tobramycin is an aminoglycoside antibiotic produced by Streptomyces tenebrarius. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death. Phosphomycin is an antibiotic that interferes with bacterial cell wall synthesis.
Revenue splits are BioMedTracker estimates.
Gilead and CURx
In February 2014, CURx entered into a global license agreement with Gilead for development for Fosfomycin:Tobramycin for Inhalation (FTI) to treat Pseudomonas aeruginosa lung infection in cystic fibrosis patients.
Partners: Gilead Sciences, Inc.
GS 9310/11 News
Pink Sheet Cystic Fibrosis Pipeline
Additional information available to subscribers only: